Atrium Health

The trials here

What the 44 trials at this site are about, from their registry records.

Conditions

• Multiple sclerosis4 trials
• Epilepsy3 trials
• Sickle cell disease3 trials
• Stroke3 trials
• Ulcerative colitis3 trials
• ALS (motor neurone disease)2 trials
• Aortic aneurysm2 trials
• Asthma2 trials
• Crohn's disease2 trials
• Heart failure2 trials
• Irritable bowel syndrome2 trials
• Multiple myeloma2 trials
• and 15 more

Phase

• Phase 314 trials
• Phase 26 trials
• Phase 1/24 trials
• Phase 2/32 trials
• Phase 11 trial
• Phase 41 trial

Status

• Recruiting15 trials
• Active, not recruiting14 trials
• Completed10 trials
• Enrolling by invitation4 trials
• Withdrawn1 trial

Lead sponsor

• Janssen Research & Development, LLC7 trials
• Wake Forest University Health Sciences4 trials
• Hoffmann-La Roche3 trials
• W.L.Gore & Associates3 trials
• Ardelyx2 trials
• and 21 more

Running trials

• Recruiting

  Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy

  NCT05871606· Phase 1· Wake Forest University Health Sciences· Source

  Contact: William Stetler, MD (principal investigator)

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

  NCT07225504· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Catherine Tsoulos

• Recruiting

  COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)

  NCT07198113· University of North Carolina, Chapel Hill· Source

  Contact: Tiffany Linville, MD

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

  NCT07149857· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Individualizing Treatment for Asthma in Primary Care (Full Study)

  NCT07052942· Phase 4· DARTNet Institute· Source

  Contact: Hazel Tapp, PhD

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT06667076· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

  NCT06422923· Phase 1/2· Neurona Therapeutics· Source

  Contact: Dianelis Diaz, RN, BSN, CRC

• Active, not recruiting

  A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

  NCT06643481· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  DISCOVERY of Risk Factors for Type 2 Diabetes in Youth

  NCT06525259· George Washington University· Source

  Contact: Merischia Griffin

• Enrolling by invitation

  Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia

  NCT06544798· Phase 2· MeiraGTx, LLC· Source

• Enrolling by invitation

  A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301

  NCT06363760· Editas Medicine, Inc.· Source

• Recruiting

  A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

  NCT06072781· Phase 3· Verastem, Inc.· Source

  Contact: Melani Terry

• Enrolling by invitation

  Evaluation of the GORE® Ascending Stent Graft

  NCT05800743· W.L.Gore & Associates· Source

• Recruiting

  The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease

  NCT05811364· W.L.Gore & Associates· Source

  Contact: Hector Crespo-Soto, MD

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

  NCT05894239· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia

  NCT05926765· Phase 2· MeiraGTx, LLC· Source

• Enrolling by invitation

  Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C

  NCT05905926· Phase 3· Ardelyx· Source

• Recruiting

  A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

  NCT05667142· Phase 3· Xenon Pharmaceuticals Inc.· Source

  Contact: Xenon Medical Affairs

• Recruiting

  Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

  NCT05135091· Phase 3· Neurona Therapeutics· Source

  Contact: Dianelis Diaz, RN, BSN, CRC

• Active, not recruiting

  A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

  NCT05269004· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Primary Care Implementation and Evaluation of Coach McLungs

  NCT05059210· Wake Forest University Health Sciences· Source

• Active, not recruiting

  A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)

  NCT04853576· Phase 1/2· Editas Medicine, Inc.· Source

• Recruiting

  Parkinson's Foundation PD GENEration Genetic Registry

  NCT04994015· Parkinson's Foundation· Source

  Contact: Kamalini Ghosh, MS

• Active, not recruiting

  A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT04586426· Phase 1/2· Janssen Research & Development, LLC· Source

• Recruiting

  NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness

  NCT04471909· Endospan Ltd.· Source

  Contact: Madelyn Smyth

• Active, not recruiting

  Natural Versus Programmed Frozen Embryo Transfer (NatPro)

  NCT04551807· Phase 3· JHSPH Center for Clinical Trials· Source

• Active, not recruiting

  HEALEY ALS Platform Trial - Master Protocol

  NCT04297683· Phase 2/3· Merit E. Cudkowicz, MD· Source

• Active, not recruiting

  Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

  NCT03970343· Impulse Dynamics· Source

• Recruiting

  GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study

  NCT03821129· W.L.Gore & Associates· Source

  Contact: Krystal Winkler

• Active, not recruiting

  A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer

  NCT03899649· Angiodynamics, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Epilepsy3 recruiting
• Aortic aneurysm2 recruiting
• Crohn's disease2 recruiting
• Stroke2 recruiting
• Acute myeloid leukaemia1 recruiting
• Asthma1 recruiting
• Childhood cancers1 recruiting
• Irritable bowel syndrome1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple sclerosis1 recruiting
• Ovarian cancer1 recruiting
• Peripheral artery disease1 recruiting
• Sickle cell disease1 recruiting
• Thalassaemia1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Withdrawn

  Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis

  NCT06841068· Phase 1/2· Wake Forest University Health Sciences· Source

• Completed

  A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06049017· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Microfragmented Adipose Tissue Compared to Corticosteroid Injection for the Treatment of Knee Osteoarthritis

  NCT05660772· Phase 3· Lipogems International spa· Source

• Recruiting

  PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

  NCT05313165· LimFlow, Inc.· Source

  Contact: Erin Towery

• Completed

  Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

  NCT05643534· Phase 3· Ardelyx· Source

• Completed

  A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery

  NCT05425056· Phase 3· Vascular Therapies, Inc.· Source

• Completed

  Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical Study

  NCT05301335· SpineX Inc.· Source

• Completed

  Prospective Analysis of In Vivo Laparoscopic Microwave Ablation Thermodynamics

  NCT05471596· Wake Forest University Health Sciences· Source

• Completed

  A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome

  NCT06734117· Hoffmann-La Roche· Source

• Completed

  Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)

  NCT04084080· Phase 3· University of Pittsburgh· Source

• Recruiting

  Early Feasibility Study - Edwards APTURE Transcatheter Shunt System

  NCT03523416· Edwards Lifesciences· Source

  Contact: Natalie Alon